| W2 Comprehensive assessment of risks and benefits of vaccines: the example of Dengue | Lucky Slamet, Stephen Thomas | 2023 | Report | Anglais |
| P4 Preparing for the next Infectious Disease Emergency | Helen Rees, Norman Baylor | | Report | Anglais |
| P3 Evolving Global Vaccine Markets | Amie Batson | 2020 | Report | Anglais |
| W9.3 Maternal influenza vaccines: How has the VIS process influenced the research agenda | Saad Omer | 2016 | Presentation | Anglais |
| W9.2 What’s Next for Gavi's Vaccine Investment Strategy: Rabies | Bernadette Abela-Ridder | 2016 | Presentation | Anglais |
| W9.1 How does Gavi make vaccine investment decisions? | Judith Kallenberg | 2016 | Presentation | Anglais |
| W8.3 Combination Vaccines: Benefits and Risks | Melissa Malhame | 2016 | Presentation | Anglais |
| W8.2 Combination Vaccines: Potential future states | Peter Dull | 2016 | Presentation | Anglais |
| W8.1 Combination Vaccines: How and Why? Lessons Learned | Michel De Wilde | 2016 | Presentation | Anglais |
| W7.3 Intestinal Microbiota and Enteric Vaccine Design | James Fleckenstein | 2016 | Presentation | Anglais |
| W7.2 The Nasal Microbiota: Diversity, Dynamicity, and Vaccine-mediated Effects | Jane Deng | 2016 | Presentation | Anglais |
| W7.1 The infant microbiome: Relevance to immune responses | María Gloria Domínguez-Bello | 2016 | Presentation | Anglais |
| W6.4 Second year of life platform and monitoring systems | Jan Grevendonk | 2016 | Presentation | Anglais |
| W6.3 Protecting Lives in the 2nd Year of Life (2YL) in Ghana | Abigail Shefer | 2016 | Presentation | Anglais |
| W6.2 Raising the Profile of an 18-month Well-child Visit: the 2YL Platform | Elicah Kandinda Kamiji | 2016 | Presentation | Anglais |
| W6.1 Global landscape analysis and literature review of 2nd year of life immunization platform | Imran Mirza | 2016 | Presentation | Anglais |
| W6.0 Intro: Establishing a Second-year-of-life (2YL) Healthy Child Visit | Rudi Eggers | 2016 | Presentation | Anglais |
| W6 Immunization in the Second Year of Life | Rebecca Fields | 2016 | Report | Anglais |
| W5.3 Good Participatory Practices for Vaccine Clinical Trials | Nelson Michael | 2016 | Presentation | Anglais |
| W5.2 African Vaccine Regulatory Forum (AVAREF): New Vision and Blueprint for Ethics and Regulatory Capacity Strengthening in Africa | Dicky Akanmori | 2016 | Presentation | Anglais |
| W5.1 WHO Regulatory Strengthening Update & LMICs Challenges in Vaccine Clinical Trial Regulation | William Wekwete | 2016 | Presentation | Anglais |
| W5 Regulatory Challenges and Constraints When Evaluating Vaccine Clinical Trials | Klaus Cichutek | 2016 | Report | Anglais |
| W4.6 Vaccines for healthcare pathogens: No ESKAPE | Jordi Rello | 2016 | Presentation | Anglais |
| W4.5 Gonococcal antimicrobial resistance and vaccines | Magnus Unemo | 2020 | Presentation | Anglais |
| W4.4 Vaccines to prevent antibiotic-resistant Staphylococcus aureus (MRSA) infections | Olaf Schneewind | 2016 | Presentation | Anglais |
| W4.3 The Role of Vaccines in Antimicrobial Resistance Strategies | Bruce Gellin | 2016 | Presentation | Anglais |
| W4.2 WHO Global Action Plan on Antimicrobial Resistance | Martin Friede | 2016 | Presentation | Anglais |
| W4.1 Introduction: Antimicrobial Resistance & Vaccines | A. A. Adeyemo | 2016 | Presentation | Anglais |
| W3.4 Vaccine technology costs and health impact assessment tool | Mercy Mvundura | 2016 | Presentation | Anglais |
| W3.3 Microarray patch case study: Measles-rubella vaccine | Darin Zehrung | 2016 | Presentation | Anglais |
| W3.2 Total System Effectiveness | Tina Lorenson | 2016 | Presentation | Anglais |
| W3.1 Introduction: Total Systems Effectiveness | Tina Lorenson | 2016 | Presentation | Anglais |
| W2.2 Public Health Criteria for Dengue Vaccine Risk/Benefit Assessment and Risk Management | Peter Smith | 2016 | Presentation | Anglais |
| W11.4 Applying TIP to low and middle income settings: a case study from South Africa | Nicola Christofides and Janine Simon-Meyer | 2016 | Presentation | Anglais |
| W11.3 Tailoring Immunization Programmes (TIP): An example of tailoring communication on vaccinations targeting hard.to.serve communities in Sweden | Ann Lindstrand | 2016 | Presentation | Anglais |
| W11.2 Vaccine Hesitancy: Determining the scale of the challenge | Susan Goldstein | 2016 | Presentation | Anglais |
| W11.1 Vaccine Hesitancy: what it means and what we need to know in order to tackle it | Robb Butler | 2016 | Presentation | Anglais |
| W10.4 Rabies antibodies for Passive Post-exposure prophylaxis | Tsepo Tsekoa | 2016 | Presentation | Anglais |
| W10.3 Gene-based Delivery of Broadly Neutralizing Antibodies for HIV Prevention | Wayne Koff | 2016 | Presentation | Anglais |
| W10.2 Passive vaccination as a global strategy for preventing RSV disease in infants | Filip Dubovsky | 2016 | Presentation | Anglais |
| W10.1 Monoclonal antibodies for infectious diseases | Martin Friede | 2016 | Presentation | Anglais |
| W1.3 Design of self-assembling protein nanomaterials as next.generation vaccine scaffolds | Neil King | 2016 | Presentation | Anglais |
| W1.2 Epitope-focused vaccine design | Bill Schief | 2016 | Presentation | Anglais |
| W1.1 Structural studies of viral envelope proteins and insights for vaccine design | Felix Rey | 2016 | Presentation | Anglais |
| W1.0 Introduction: Applying Novel Technologies to Vaccine Development | Rino Rappuoli | 2016 | Presentation | Anglais |
| W9 Gavi's Vaccine Investment Strategy (VIS) | Helen Rees | 2016 | Report | Anglais |
| W8 Combination Vaccines: Why and How? | A. A. Adeyemo | 2016 | Report | Anglais |
| P6.4 Preferred Product Characteristics | David Kaslow | 2016 | Presentation | Anglais |
| P6.3 Schistosomiasis Vaccine Updates | Annie Mo | 2016 | Presentation | Anglais |
| P6.2 Vaccine development for Group A Streptococcus | Andrew Steer | 2016 | Presentation | Anglais |
